{"id":62229,"date":"2025-11-19T10:06:30","date_gmt":"2025-11-19T09:06:30","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/"},"modified":"2025-11-19T10:06:30","modified_gmt":"2025-11-19T09:06:30","slug":"biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/","title":{"rendered":"Biocentis secures $19M to revolutionize insect control through programmable biology"},"content":{"rendered":"
\n

LONDON & MILAN–(BUSINESS WIRE)–#AI<\/a>–Biocentis, a life-science company at the forefront of genetic innovation, has raised $19 million to advance its mission of protecting health, agriculture, and biodiversity from the growing global threats posed by insects.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe financing includes a $13M seed equity investment led by the Grantham Foundation for the Protection of the Environment (US) and Algebris Investments (Europe), and a $6M award from Wellcome, one of the world\u2019s leading global health foundations.<\/p>\n

\nA spin-out of Imperial College London, Biocentis leverages a proprietary genome engineering platform to develop insects carrying genetic traits that reduce fertility within the target species. When released, these insects mate with wild populations, lowering their numbers while leaving other species and the environment unaffected.<\/p>\n

\nAt the same time, Biocentis applies AI to simulate how biological systems perform in real-world environments, accelerating development and helping anticipate emerging insect-borne risks.<\/p>\n

\nInsects are vital to our planet, yet some species cause devastating damage. Disease-carrying insects infect hundreds of millions of people each year, causing almost a million deaths. Agricultural pests destroy up to 25% of global crop yields, while invasive insects drive native species toward extinction. Rising temperatures and international trade are extending the reach of many species, turning localized challenges into global problems.<\/p>\n

\n\u201cFor over a century, we have relied on chemical pesticides, but insects evolve faster than chemical interventions, and the collateral damage to people and the environment continues to mount,\u201d said Giorgio Rocca, Co-founder and CEO of Biocentis. \u201cAdvances in genetics now let us control harmful insect populations with precision while preserving the health of surrounding ecosystems.\u201d<\/p>\n

\nThe first solutions in Biocentis\u2019 portfolio target a mosquito that vectors diseases such as dengue, Zika, yellow fever, and chikungunya (Aedes aegypti), as well as a fruit fly that threatens global fruit production (Drosophila suzukii). But this is just the beginning, as Biocentis\u2019 programmable biology platform can be extended to tackle a broad spectrum of harmful species.<\/p>\n

\nWith this funding, Biocentis will advance its first solutions into field trials across the Americas and beyond, while further expanding its platform to new applications.<\/p>\n

\nAbout Biocentis<\/b><\/p>\n

\nBiocentis is a life-science company and spin-out of Imperial College London re-imagining insect control with a unique technology platform that combines environmental sustainability and unprecedented effectiveness. Find out more at: www.biocentis.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nFor media inquiries, please contact: press@biocentis.com<\/a>.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LONDON & MILAN–(BUSINESS WIRE)–#AI–Biocentis, a life-science company at the forefront of genetic innovation, has raised $19 million to advance its mission of protecting health, agriculture, and biodiversity from the growing global threats posed by insects. The financing includes a $13M seed equity investment led by the Grantham Foundation for the Protection of the Environment (US) … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62229","6":"format-standard","7":"category-industry"},"yoast_head":"\nBiocentis secures $19M to revolutionize insect control through programmable biology - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocentis secures $19M to revolutionize insect control through programmable biology - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LONDON & MILAN–(BUSINESS WIRE)–#AI–Biocentis, a life-science company at the forefront of genetic innovation, has raised $19 million to advance its mission of protecting health, agriculture, and biodiversity from the growing global threats posed by insects. The financing includes a $13M seed equity investment led by the Grantham Foundation for the Protection of the Environment (US) ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-19T09:06:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251119917075\/en\/2646592\/22\/Biocentis-logo-fullcolor.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Biocentis secures $19M to revolutionize insect control through programmable biology\",\"datePublished\":\"2025-11-19T09:06:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\\\/\"},\"wordCount\":399,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251119917075\\\/en\\\/2646592\\\/22\\\/Biocentis-logo-fullcolor.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\\\/\",\"name\":\"Biocentis secures $19M to revolutionize insect control through programmable biology - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251119917075\\\/en\\\/2646592\\\/22\\\/Biocentis-logo-fullcolor.jpg\",\"datePublished\":\"2025-11-19T09:06:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251119917075\\\/en\\\/2646592\\\/22\\\/Biocentis-logo-fullcolor.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251119917075\\\/en\\\/2646592\\\/22\\\/Biocentis-logo-fullcolor.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocentis secures $19M to revolutionize insect control through programmable biology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biocentis secures $19M to revolutionize insect control through programmable biology - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/","og_locale":"en_US","og_type":"article","og_title":"Biocentis secures $19M to revolutionize insect control through programmable biology - Pharma Trend","og_description":"LONDON & MILAN–(BUSINESS WIRE)–#AI–Biocentis, a life-science company at the forefront of genetic innovation, has raised $19 million to advance its mission of protecting health, agriculture, and biodiversity from the growing global threats posed by insects. The financing includes a $13M seed equity investment led by the Grantham Foundation for the Protection of the Environment (US) ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/","og_site_name":"Pharma Trend","article_published_time":"2025-11-19T09:06:30+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251119917075\/en\/2646592\/22\/Biocentis-logo-fullcolor.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Biocentis secures $19M to revolutionize insect control through programmable biology","datePublished":"2025-11-19T09:06:30+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/"},"wordCount":399,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251119917075\/en\/2646592\/22\/Biocentis-logo-fullcolor.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/","url":"https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/","name":"Biocentis secures $19M to revolutionize insect control through programmable biology - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251119917075\/en\/2646592\/22\/Biocentis-logo-fullcolor.jpg","datePublished":"2025-11-19T09:06:30+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251119917075\/en\/2646592\/22\/Biocentis-logo-fullcolor.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251119917075\/en\/2646592\/22\/Biocentis-logo-fullcolor.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/biocentis-secures-19m-to-revolutionize-insect-control-through-programmable-biology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biocentis secures $19M to revolutionize insect control through programmable biology"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62229","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62229"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62229\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}